Our study aimed to predict clinically significant PCa in patients with PSA ≤ 20 ng/mL by employing our deep learning approach on multimodal medical data routinely used in clinical practice without prostate biopsy, which can be used to optimize the overall management of PCa. The gene discussed is KLK3; the disease is posterior cortical atrophy.